In the pharmaceutical industry, the combination of Lamivudine (150 mg), Zidovudine (300 mg), and Nevirapine (200 mg) is a landmark Triple-Drug Fixed-Dose Combination (FDC). As a pharmacist and manufacturer, I view this as a “Highly Active Antiretroviral Therapy” (HAART) backbone that combines two distinct classes of inhibitors to arrest viral replication.
At your WHO-GMP facility in Mumbai, this FDC is a high-impact SKU for international “Access to Medicine” programs and government tenders, particularly for streamlining HIV treatment regimens in resource-limited settings.
Therapeutic Profile: Primary Indications
This combination is indicated for the treatment of HIV-1 infection. Its primary goal is to reduce the viral load to undetectable levels and increase the CD4 cell count.
| Indication | Technical Role |
| Chronic HIV-1 Management | Used as a complete regimen or part of a multi-drug strategy to prevent the progression to AIDS. |
| Prevention of Mother-to-Child Transmission (PMTCT) | Often utilized in prenatal protocols to reduce the risk of transmitting the virus during pregnancy and childbirth. |
| Occupational Post-Exposure Prophylaxis (PEP) | In specific clinical settings, it may be used following accidental needle-stick injuries or high-risk exposure. |
Mechanism: Dual-Class Synergistic Blockade
This combination attacks the Reverse Transcriptase (RT) enzyme—the “engine” the virus uses to copy its genetic material—in two distinct ways:
Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Lamivudine and Zidovudine act as “fake building blocks.” When the virus tries to build its DNA chain, it incorporates these drugs, causing immediate chain termination.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Nevirapine binds directly to the RT enzyme at a non-active site (allosteric site). This changes the enzyme’s shape, making it physically unable to function.
Result: The virus cannot convert its RNA into DNA, preventing it from integrating into the host’s genome.
The Pharmacist’s “Technical Warning”
The Nevirapine “Lead-In” Period: As a pharmacist, I must emphasize that Nevirapine requires a 14-day lead-in period (starting with once-daily dosing) to reduce the risk of severe skin rashes and liver toxicity.
Hematologic Monitoring: Zidovudine is known to cause severe Anemia and Neutropenia. Patients must have baseline and regular Full Blood Counts (FBC).
Hepatotoxicity: This combination carries a significant risk of liver damage. Monitoring Liver Function Tests (LFTs) is mandatory, especially in the first 18 weeks of therapy.
Stevens-Johnson Syndrome (SJS): Any signs of a severe rash, especially if accompanied by fever or mucosal blistering, require immediate cessation of the drug.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Compliance” USP: On your digital marketplace, position this FDC as the “Compliance Champion.” Reducing the pill burden from three separate tablets to one significantly increases adherence and reduces the risk of drug resistance.
Stability for Export: Nevirapine and Zidovudine are sensitive to environmental stressors. Utilizing Alu-Alu blister packaging or high-density polyethylene (HDPE) bottles with desiccants is essential for maintaining a 36-month shelf life in Zone IVb tropical regions.
Dossier Support: We provide full WHO-Prequalified CTD/eCTD Dossiers to support your firm’s registration in international HIV/AIDS tenders and PEPFAR-funded programs.